Canaccord initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Speculative Buy rating and C$9 price target In May 2024, the company shifted focus from knee osteoarthritis to eosinophilic esophagitis, a chronic, immune-mediated condition of the esophagus with rising prevalence and limited treatment options, the analyst tells investors in a research note. The firm says data from the ongoing Phase 1b/2a of Eupraxia’s lead candidate, EP-104GI, suggest the product could offer “unprecedented durability and safety, potentially establishing it as a first-line treatment with annual dosing.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX:
- Eupraxia Pharmaceuticals Strengthens Governance with Board Elections and Strategic Approvals
- Eupraxia Pharmaceuticals to Host Virtual Event on EoE Treatment Study
- Eupraxia Pharmaceuticals reports Q1 net loss $6.8M vs. $6.2M last year
- Eupraxia Pharmaceuticals Reports Q1 2025 Financial Results
- Eupraxia Pharmaceuticals Reports Positive Nine-Month Outcomes in EoE Trial